CORDIS Project
Funding breakdown and partner intelligence are Premium
Sign in and upgrade to Premium for EU contribution totals, consortium analytics, OpenAlex research context, and AI summaries. · 0 consortium intelligence fields visible of 1
Start free • Cancel anytime • 14-day refund guarantee
Nanosynex is developing a rapid antibiotic susceptibility testing technology that significantly reduces the time required to obtain results. This innovation aims to improve treatment accuracy and reduce hospitalization times, addressing the urgent issue of antimicrobial resistance.
Antimicrobial Resistance (AMR) has been declared as one of today’s biggest global threats as 700,000 people die due AMR.Inappropriate antibiotic use is widespread.
In the general practice, physicians commonly use empirical antibiotic therapy (highly inaccurate), since AST results take too long.
Nanosynex product provides a revolutionary ultra-fast AST technology that will disrupt the market by cutting time to results in more than half (from 9 – the fastest - to 4 hours).
This will allow physicia…
Partner organizations (coordinator is shown above), with normalized type and CORDIS activity type. Guests see up to 4 partners.
Similar projects, consortium collaboration history, frequent partners, and OpenAlex research context.
Guests see up to 5 EuroSciVoc fields.
Guests see up to 5 topics.
